Ovarian Cancer in the Elderly: Time to Move towards a More Logical Approach to Improve Prognosis-A Study from the FRANCOGYN Group.
chemotherapy
elderly
frailty
ovarian cancer
surgery
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
04 May 2020
04 May 2020
Historique:
received:
31
03
2020
revised:
23
04
2020
accepted:
28
04
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
8
5
2020
Statut:
epublish
Résumé
Elderly and/or frail women with ovarian cancer are often undertreated. The aim of the study is to compare the effects of age and frailty on surgical approaches, postoperative complications, and prognosis in elderly women with ovarian cancer. A retrospective multicenter study of women ≥70 years were treated for ovarian cancer at seven French university hospitals between 2007 and 2015. Of the 1119 women treated for ovarian cancer during the study period, 147 were ≥70 years and had complete data. Of these women, 65 were aged 70-74 years, and 82 were aged ≥75 years. Overall, 77% of the younger women (49/65) received optimal treatment compared with 51% (40/82) of the older women ( Surgeons modify their approach to treating ovarian cancer in women ≥75 years probably to reduce immediate postoperative complications. The prognosis is significantly worse in patients with greater frailty. Improvements to the sequence of treatments administered, with priority given to neoadjuvant chemotherapy in patients with greater frailty, could help increase the number of women who receive optimal treatment and improve their prognosis.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Elderly and/or frail women with ovarian cancer are often undertreated. The aim of the study is to compare the effects of age and frailty on surgical approaches, postoperative complications, and prognosis in elderly women with ovarian cancer.
METHODS
METHODS
A retrospective multicenter study of women ≥70 years were treated for ovarian cancer at seven French university hospitals between 2007 and 2015.
RESULTS
RESULTS
Of the 1119 women treated for ovarian cancer during the study period, 147 were ≥70 years and had complete data. Of these women, 65 were aged 70-74 years, and 82 were aged ≥75 years. Overall, 77% of the younger women (49/65) received optimal treatment compared with 51% (40/82) of the older women (
CONCLUSIONS
CONCLUSIONS
Surgeons modify their approach to treating ovarian cancer in women ≥75 years probably to reduce immediate postoperative complications. The prognosis is significantly worse in patients with greater frailty. Improvements to the sequence of treatments administered, with priority given to neoadjuvant chemotherapy in patients with greater frailty, could help increase the number of women who receive optimal treatment and improve their prognosis.
Identifiants
pubmed: 32375360
pii: jcm9051339
doi: 10.3390/jcm9051339
pmc: PMC7291201
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Oncol. 2018 Nov;151(2):269-274
pubmed: 30253875
J Geriatr Oncol. 2016 Sep;7(5):354-61
pubmed: 27499341
Gynecol Oncol. 2015 Sep;138(3):554-9
pubmed: 26093061
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Gynecol Oncol. 2007 Oct;107(1):99-106
pubmed: 17602726
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Gynecol Oncol. 2020 Jan;31(1):e6
pubmed: 31788996
Oncotarget. 2017 Feb 14;8(7):12389-12405
pubmed: 27852039
Gynecol Oncol. 2011 Jan;120(1):23-8
pubmed: 20933255
Int J Gynecol Cancer. 2018 May;28(4):729-737
pubmed: 29498983
Gynecol Oncol. 2018 May;149(2):270-274
pubmed: 29514738
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:59-78
pubmed: 30306591
Aging Dis. 2017 Oct 1;8(5):677-684
pubmed: 28966809
BMC Cancer. 2015 Nov 26;15:937
pubmed: 26610814
J Obstet Gynaecol. 2017 Nov;37(8):1070-1075
pubmed: 28741395
Eur J Obstet Gynecol Reprod Biol. 2019 May;236:214-223
pubmed: 30905627
Arch Gynecol Obstet. 2012 Dec;286(6):1545-8
pubmed: 22843035
Ann Surg. 1995 Feb;221(2):124-32
pubmed: 7857141
J Clin Oncol. 2007 Nov 1;25(31):4946-51
pubmed: 17971592
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Int J Gynecol Cancer. 2017 Nov;27(9):1863-1871
pubmed: 28763363
N Engl J Med. 2019 Feb 28;380(9):822-832
pubmed: 30811909
Ann Surg Oncol. 2006 Aug;13(8):1156-61
pubmed: 16791447
Perspect Clin Res. 2015 Oct-Dec;6(4):184-9
pubmed: 26623388
Gynecol Oncol. 2017 Oct;147(1):104-109
pubmed: 28734497
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Gynecol Oncol. 2018 Jun;149(3):525-530
pubmed: 29550184